Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Free Cash Flow of -$12.1 million for Q1 2026, down 192.93% year-over-year from $13.0 million in Q1 2025, and down 60.45% quarter-over-quarter from -$7.5 million in Q4 2025.
Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Free Cash Flow data on file, last reported at -$12.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$12.1 million, down 192.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.7 million (down 84.26% YoY), and the FY2025 annual result was -$27.8 million, down 45.18% from the prior year.
- Free Cash Flow eased to -$12.1 million in Q1 2026 per IKT's latest filing, from -$7.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$3.4 million in Q4 2023 and troughed at -$12.1 million in Q1 2026.
- A 5-year average of -$5.6 million and a median of -$4.9 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow jumped 35.25% in 2024, then slumped 192.93% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$3.6 million in 2022, then climbed by 3.2% to -$3.4 million in 2023, then tumbled by 55.28% to -$5.3 million in 2024, then sank by 40.6% to -$7.5 million in 2025, then slumped by 60.45% to -$12.1 million in 2026.
- Business Quant data shows IKT's Free Cash Flow at -$12.1 million in Q1 2026, -$7.5 million in Q4 2025, and -$10.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -12.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.06 Mn |
| Mar 31, 2026 | -12.06 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Mar 31, 2025 | -4.12 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Mar 31, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.87 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Dec 31, 2023 | -3.44 Mn |